TABLE 2.
Univariate Survival Analyses
| OS | PFS | |||
|---|---|---|---|---|
| Parameter | Median OS | Significance* | Median PFS | Significance* |
| Age | P = 0.046 | P = 0.014 | ||
| Median < 63 y, n = 22 | 16.33 (9.39–23.27) | 10.41 (7.07–13.76) | ||
| Median ≥ 63 y, n = 23 | 9.69 (7.28–12.11) | 5.88 (3.46–8.30) | ||
| Sex | P = 0.330 | P = 0.259 | ||
| Male, n = 27 | 10.48 (2.90–18.06) | 6.41 (3.12–9.70) | ||
| Female, n = 18 | 10.84 (8.32–13.37) | 9.69 (5.94–13.45) | ||
| MGMT promoter methylation status | P = 0.032 | P = 0.028 | ||
| Methylated, n = 12 | 19.38 (3.16–35.61) | 10.84 (4.60–17.09) | ||
| Unmethylated, n = 33 | 10.42 (8.60–12.23) | 7.26 (4.49–10.03) | ||
| TERT promoter mutation status | P = 0.939 | P = 0.896 | ||
| Mutant, n = 39 | 10.42 (8.04–12.79) | 7.69 (4.99–10.38) | ||
| Wild-type, n = 6 | 11.30 (6.93–15.70) | 8.35 (3.02–13.67) | ||
| KPS | P = 0.117 | P = 0.104 | ||
| Median < 80, n = 26 | 8.61 (4.83–12.38) | 6.21 (4.32–8.10) | ||
| Median ≥ 80, n = 19 | 17.77 (13.15–22.40) | 9.69 (7.54–11.84) | ||
| Mode of radiotherapy | P = 0.105 | P = 0.175 | ||
| Conventional, n = 23 | 16.33 (11.48–21.18) | 8.90 (7.41–10.40) | ||
| Hypofractionated, n = 22 | 6.83 (0.72–12.95) | 5.29 (2.61–7.97) | ||
| Conventional radiochemotherapy | P = 0.081 | P = 0.024 | ||
| ≥ 1 cycle adjuvant temozolomide, n = 12 | 19.29 (13.99–24.58) | 10.42 (8.93–11.90) | ||
| No adjuvant temozolomide, n = 11 | 9.86 (3.67–16.04) | 6.21 (5.50–6.92) | ||
| Hypofractionated radiotherapy | P = 0.064 | P = 0.100 | ||
| With concomitant temozolomide, n = 13 | 10.84 (0.0–26.94) | 8.08 (1.21–14.96) | ||
| Without concomitant temozolomide, n = 9 | 6.83 (1.16–12.51) | 5.29 (3.98–6.60) | ||
| Mode of surgery | P = 0.118 | P = 0.443 | ||
| Stereotactic biopsy, n = 35 | 9.86 (7.31–12.41) | 6.83 (3.90–9.77) | ||
| Microsurgical resection, n = 10 | 19.29 (16.77–21.80) | 8.35 (2.61–7.97) | ||
| Contrast enhancement | P = 0.070 | P = 0.419 | ||
| Yes, n = 40 | 9.86 (8.63–11.08) | 6.83 (4.54–9.13) | ||
| No, n = 5 | 21.22 (17.42–25.03) | 10.61 (7.79–13.43) | ||
| CE-T1w MRI volume | P = 0.289 | P = 0.372 | ||
| Median < 11.1 mL, n = 23 | 15.77 (7.90–23.64) | 8.90 (7.52–10.29) | ||
| Median ≥ 11.1 mL, n = 22 | 6.21 (0.70–11.72) | 5.65 (3.65–7.65) | ||
| T2w MRI volume | P = 0.031 | P = 0.118 | ||
| Median < 40.9 mL, n = 23 | 17.77 (6.20–29.34) | 8.90 (6.47–11.33) | ||
| Median ≥ 40.9 mL, n = 22 | 6.83 (1.32–12.35) | 5.65 (2.90–8.41) | ||
| TSPO polymorphism genotype | P = 0.360 | P = 0.333 | ||
| LAB | 10.84 (8.91–12.77) | 9.69 (5.91–13.48) | ||
| MAB | 17.77 (7.99–27.56) | 8.90 (4.76–13.05) | ||
| HAB | 8.28 (0.78–15.79) | 5.29 (3.72–6.86) | ||
| SUVmax | P = 0.037 | P = 0.333 | ||
| Median < 2.2, n = 23 | 17.77 (4.40–31.14) | 8.41 (7.56–9.23) | ||
| Median ≥ 2.2, n = 22 | 8.28 (3.67–12.89) | 6.83 (3.63–10.04) | ||
*
Bold font highlights the statistically significant associations.
MGMT = O6-alkylguanine DNA methyltransferase gene; TERT = telomerase reverse transcriptase gene; KPS = Karnofsky performance status scale; CE-T1w = contrast-enhanced T1-weighted; T2w = T2-weighted.
Data in parentheses are 95% CI.